Similar conclusions have been drawn by two other reviews [5,6], one showing a small or no reduction [6], the other no significant effect [5] on prostate cancer-specific mortality A recently population-based cohort study showed a possible greater benefit in high-risk men aged 60 with PSA ≥ 2 ng/mL [7]. The gene discussed is KLK3; the disease is prostate cancer.